# AMSilk

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amsilk

- Industry: Materials
- Headquarters: Munich, Germany
- Website: www.amsilk.com
- Total disclosed funding: $100M
- Latest round: Series C (Jun 5, 2024)
- Investors on record: 6

## About

AMSilk GmbH, based in Munich, Germany, specializes in developing innovative Biogenius Materials derived from silk proteins, setting new benchmarks in sustainable material solutions.Founded in 2008, AMSilk GmbH operates as a biotechnology company focused on the production of silk-based materials. The company, led by co-founder Thomas Scheibel, has not reported any significant business pivots or subsidiary relationships. As of March 2023, AMSilk raised EUR 25 million in a Series C funding round led by AT Newtec, valuing the company at USD 128.82 mn. This funding was aimed at supporting the company's ongoing industrialization efforts.AMSilk specializes in the development and production of Biogenius Materials derived from silk proteins, offering a range of products including fibers, yarns, sprayable formulations, hydrogels, and silk powder. These products are engineered for applications in textiles, medical uses, and consumer goods, catering to a global clientele across Europe and North America. In 2023, AMSilk reported zero revenue with an EBITDA of EUR -5,505,363.60. The company’s revenue generation strategies include partnerships and B2B transactions, focusing on customized solutions for clients in various sectors, including textiles and medical devices. Their flagship product lines, AMSilk4Shine and AMSilk4Care, target the consumer care market, emphasizing the superior quality of their biogenic materials. In June 2025, AMSilk GmbH raised EUR 30 million in venture funding led by returning investor AT Newtec, with participation from other returning investors Novo Holdings and MIG Capital. The round was part of a larger EUR 52 million equity and debt funding. The company plans to use the September 2025 funding to scale up industrial production and expand commercial operations of its bio-fabricated silk protein materials.

## Funding rounds

- Series C, Jun 5, 2024, $32M — Novo Holdings, MIG Capital, AT Newtec
- Series C, Mar 22, 2023, $27M — MIG Capital, Cargill Inc., AT Newtec, Novo Holdings
- Series C, Apr 1, 2021, $34M — MIG Capital, Cargill Inc., Novo Holdings, Athos Service, E.R. Capital Holding
- Series B, Dec 21, 2010, $6.6M — MIG Capital, AT Newtec

## Investors

- MIG Capital (https://capitalatlas.ai/funds/mig-capital) — Series B, Series C
- AT Newtec — Series B, Series C
- Cargill Inc. — Series C
- Novo Holdings — Series C
- Athos Service — Series C
- E.R. Capital Holding — Series C